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Graves’ ophthalmopathy (GO) is a chronic autoimmune process that
affects the orbital tissues and it is generally associated with Graves’ thy-
roid disease. As other autoimmune diseases, GO is multifactorial and de-
pendent upon the interaction among environmental, genetic and endoge-
nous factors(1-2). Smoking is the most clearly identified risk factor, and there
is an association between the severity of the disease and the amount of
smoked cigarettes(1-2). During the inflammatory stage of the disease, there
is an infiltration of the orbital tissues by lymphocytes and macrophages(1-3),
with release of several cytokines, mostly interleukin 1 (IL-1), tumor necrosis
factor-α (TNF-α) and inte-γ (IFN-γ), that induces the production of glycosa-
minoglycans by fibroblasts. In later stages, fibrosis with restriction and
atrophy of the extraocular muscles accounts for the clinical dysfunction(1).
Colchicine is an alkaloid that has been used for an increasing number of
diseases due to its anti-inflammatory effects(4-5); it reduces motility, chemo-
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Purpose: To investigate if colchicine is valuable in the treatment of
Graves’ ophthalmopathy (GO), we compared its effect with prednisone
in 22 patients during the inflammatory phase of GO. Methods: All
patients, similar in age, sex and smoking habits, were euthyroid for at least
3 months and randomly divided into two groups, one treated with
colchicine (1.5 mg/day) and the other treated with prednisone (0.75 mg/
kg/day). They were monitored with ophthalmologic assessment (clinical
activity score-CAS) and magnetic resonance imaging, using a signal
intensity ratio (SIR) of the recti muscles in comparison to the cerebral
substantia alba. Results: Amelioration of CAS was seen in 68% of the
orbits in both groups. SIR also had a significant reduction after treatment:
the initial median of 1.14 in G1 and 1.27 in G2, evolved, after treatment, to
1.07 in G1 and 0.69 in G2. The variation between both groups after treatment
was not significant (p=0.22). None of the patients treated with colchicine
had side effects; on the other hand, side effects in G2 were weight gain,
edema, gastric complaints, hirsutism, weakness, depression, and alterations
in blood pressure. Conclusion: Colchicine had a beneficial effect on the
inflammatory phase of GO without the side effects of prednisone.
ABSTRACT
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taxis, phagocytosis and adhesiveness of polymorphonuclear
cells, as well as the activity of proinflammatory enzymes(6-9). In
addition, it decreases the production of TNF-α and TNF-α
mRNA levels, the expression of adhesion molecules and IL-2
receptors and the synthesis of IL-6(10-14). Furthermore, it inhi-
bits the production of IL-1 by neutrophils and induces an
increased IL-1 production by macrophages(15-16). It is also a
potent inhibitor of fibroblast and lymphocyte functions and
proliferation(14).
Corticosteroids are the first-choice immunosuppressive
treatment for GO, but cause important side effects(17). To in-
vestigate if colchicine could be an appropriate therapy for
patients with inflammatory GO due to its good tolerability and
possible action on GO etiological factors, we performed this
prospective and randomized study to compare its efficacy and
side effects with those of oral prednisone.
METHODS
Patients
Twenty-five patients with untreated and active inflammato-
ry stage of the eye disease, GO classes II-IV(18), 16 females and
9 males aged 23 to 66 years (median 41 years) were admitted to
the Orbital Center of “Hospital São Paulo”, a teaching hospital
of the Federal University of São Paulo, in São Paulo, Brazil from
1999 to 2000. All patients had GO of less than 18 months of
duration and were euthyroid for at least 3 months (independen-
tly of the type of treatment for the thyroid disease - Table 1), as
indicated by physical examination and normal values of serum
free thyroxine (fT4: 0.6-1.5 ng/dL; Delfia fluoroimmunoassay -
IFMA) and thyrotropin (TSH: 0.3-5 mU/L; IFMA).
Methods
Ophthalmologic evaluation and magnetic resonance ima-
ging (MRI).
The GO activity was evaluated by the clinical activity score
(CAS) suggested by Mourits et al.(19), and by the signal inten-
sity of the extraocular muscles (superior, medial, inferior and
lateral) on MRI. This signal intensity was measured and expres-
sed as a ratio (SIR) between extraocular muscles and cerebral
substantia alba(20-21). MRI was performed in coronal planes T2
using a 1.0 T superconducting MR unit gyroscan T10-NT
(Philips). To evaluate the results obtained after treatment we
have chosen the two more involved muscles. Patients and
physicians who assigned the pre- and post-treatment CAS and
MRI scans were blinded regarding the treatment group. Pa-
tients with optic neuropathy, diabetes mellitus, hypertension,
hepatic and kidney disease, or gastrointestinal complaints were
not included. Patients with insufficient follow-up, or who deve-
loped abnormal thyroid function during the study were exclu-
ded. The trial was approved by the Committee of Medical Ethics
of our institution and a written informed consent was obtained
from all patients.
Treatment and follow-up
Patients were randomized by random permuted blocks
(blocking) in two groups(22-23). Group 1 (G1, n=12) was treated
with a single oral dose of colchicine 1.5 mg/day for 1 month
and thereafter with a dose of 1.0 mg/day for 2 more months.
Group 2 (G2, n=13) received oral prednisone 0.75 mg/kg/day
for 1 month and, subsequently, decreasing doses for 2 more
months. Both groups were similar regarding age, sex and smo-
king habits (Table 1). Both drugs were supplied to the patients
to obtain better compliance. Follow-up examinations were per-
formed at the beginning of the treatment and 1 and 3 months
after. Routine laboratory tests were performed monthly. One
patient in G1 was excluded due to the development of hypo-
thyroidism during the period of the study. Two patients in G2
were excluded due to side effects of prednisone (hyperten-
sion, weight gain and edema).
To assess the efficacy of both forms of treatment the
patients were evaluated by measuring CAS and MRI before
and three months after the therapy. The success of each form
of treatment was defined as a decrease in CAS from inflamma-
tory (≥ 4) to stable (≤ 3) and a reduction of the signal intensity
ratio on MRI.
Statistical analysis
The CAS and SIR results were analyzed with the GraphPad
InStat (Instat Inc., USA) software package V2.02. For sta-
Table 1. Characteristics of patients with Graves' ophthalmopathy
that received colchicine or prednisone
Patient Age Sex Treatment for Smoking
thyroid disease habits
Group 1 - Colchicine
01 41 Female Metimazole + l-thyroxine Yes
02 25 Male Radioiodine No
03 40 Male l-thyroxine after Radioiodine No
04 35 Male l-thyroxine after Radioiodine No
05 42 Male Euthyroidism Yes
06 48 Female Metimazole Yes
07 58 Female Remission of hyperthyroidism No
08 58 Female Metimazole Yes
09 66 Male Propiltiouracil + l-thyroxine No
10 44 Female Remission of hyperthyroidism Yes
11 51 Female L-thyroxine after thyroidectomy Yes
Group 2 - Prednisone
12 49 Female Remission of hyperthyroidism Yes
13 53 Female l-thyroxine after thyroidectomy No
14 31 Female Euthyroidism Yes
15 32 Female l-thyroxine after Radioiodine Yes
16 55 Male Metimazole No
17 35 Female Euthyroidism Yes
18 31 Female l-thyroxin after Metimazole Yes
19 43 Female l-thyroxin after thyroidectomy No
20 52 Female Euthyroidism No
21 23 Male l-thyroxine after thyroidectomy No
22 24 Male Euthyroidism No
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tistical analysis of the treatment outcome by CAS, only data of
inflamed orbits (CAS ≥ 4) were considered. For the SIR evalua-
tion we selected the two more inflamed muscles. The Mann-
Whitney test was used for comparison between groups and
between smokers and non-smokers before treatment. Pre- and
post-treatment values were compared by the one-tailed Wil-
coxon rank sum test. Fisher’s exact probability test was used
for the analysis of effectiveness between groups. To compare
the percentage of variation we used the one-tailed Mann-
Whitney test. For all tests p≤0.05 was considered significant.
RESULTS
All 22 patients remained euthyroid during the study sho-
wing normal values of serum fT4 and TSH. At the end of the
treatment all of them showed symptomatic relief and improve-
ment in appearance.
The initial median CAS in G1 was 5.0 and, after treatment,
was altered to 3.0. Similarly, in G2, the initial median CAS was
4.0 and, after treatment, was changed to 1.0. Therefore, under
both treatments, a significant reduction in CAS was observed
(p<0.0001 for G1 and p=0.0003 for G2, Table 2 and Figure 1).
After 3 months the therapeutic effect was similar in both
groups, with 13 of 18 orbits (72%) with inflammatory disease in
G1 responding to colchicine and 16 of 17 orbits (94%) in G2
responding to prednisone (p=0.12). When we considered a
more strict outcome, the improvement of at least 2 points in
CAS of all orbits, 15 orbits in G1 (68%) and 15 orbits in G2
(68%) showed amelioration of disease activity and, again, the
therapeutic effect was identical in both groups.
The evaluation of SIR revealed a significant reduction after
treatment in both groups (Table 2 and Figure 2). Thus, the initial
median SIR in G1 was 1.14 and, after treatment, changed to 1.07
(p=0.01). The initial median in G2 was 1.27 and, after treatment,
was modified to 0.67 (p=0.01). There was no statistical diffe-
rence in the initial SIR between both groups (p=0.80). In addi-
tion, the percentage of variation between groups was also not
significant, G1=0.16 and G2=0.38 (p=0.22).
None of the patients in G1 had side effects with the emplo-
yed dose of colchicine. On the other hand, in G2, besides
Table 2. Clinical activity score (CAS) and mean signal intensity ratio
(SIR) of the two more inflamed muscles of patients with Graves' oph-
thalmopathy before and after treatment with colchicine or prednisone
Patient Orbit CAS CAS SIR SIR
before after before after
treatment treatment treatment treatment
Group 1 - Colchicine
1 Right 6 3 1.13 0.74
Left 2 1 0.98 0.49
2 Right 4 2 1.15 0.94
Left 5 3 0.99 1.05
3 Right 4 0 0.88 0.77
Left 0 0 0.79 0.75
4 Right 5 2
Left 5 3
5 Right 5 2 1.27 1.04
Left 8 5 1.29 1.08
6 Right 4 3 1.10 1.14
Left 5 3 1.23 1.31
7 Right 5 3 1.98 1.68
Left 4 3 2.09 1.74
8 Right 6 5 1.62 1.60
Left 6 4 1.53 1.31
9 Right 5 2
Left 3 2
10 Right 7 4 1.02 1.18
Left 7 5 0.83 0.93
11 Right 3 2
Left 4 2
Group 2 - Prednisone
12 Right 5 1 1.14 0.69
Left 2 1 0.80 1.09
13 Right 4 1 1.39 0.50
Left 4 1 1.39 0.36
14 Right 4 1
Left 0 0
15 Right 3 2 0.74 0.58
Left 4 1 0.69 0.77
16 Right 5 3 1.91 1.59
Left 4 2 1.74 1.20
17 Right 4 1
Left 1 0
18 Right 5 3
Left 5 3
19 Right 4 1 2.03 0.62
Left 4 1 1.95 0.64
20 Right 5 2
Left 4 4
21 Right 3 2 0.43 0.63
Left 4 1 0.69 0.74
22 Right 5 3
Left 0 0
Figure 1 - Comparison of the clinical activity score (CAS) of patients
with Graves’ ophthalmopathy before (white bars) and after treatment
(black bars) with colchicine (n=11) or prednisone (n=11); under both
treatments, a significant reduction in CAS was observed (p<0.0001 for
G1* and p=0.0003 for G2**)
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those 2 patients excluded due to adverse reactions, there were
additional side effects related to prednisone, as weight gain (3
patients), edema (3 patients), gastric complaints (2 patients),
hirsutism (1 patient), weakness (1 patient), depression (1 pa-
tient), and hypertension (4 patients).
On comparison between smokers and nonsmokers, inde-
pendently of the treatment, there was a tendency for nonsmo-
kers to present lower values of initial CAS (p=0.08). Additio-
nally, 10 of 15 orbits with inflammatory disease in smokers
(66%) responded to treatment, when compared with 18 of 19
orbits of nonsmokers (94%), but this is not statistically signi-
ficant (p=0.06).
DISCUSSION
Graves’ ophthalmopathy can be an incapacitating eye di-
sease in the most severe cases, causing disfiguring proptosis,
pain, redness, swelling of the eyelids, grittiness of the eyes,
diplopia, and even blindness(1,24). In the active phase, lympho-
cytic infiltration and secretion of various cytokines induce
glycosaminoglycan (GAG) production by fibroblasts(25-26).
Due to their hydrophilic nature, GAG contribute to interstitial
edema and swelling of the orbital tissue in GO, leading to the
clinical expression of the disease(27).
Anti-inflammatory treatment can be applied in the active
stage. The most used treatments are corticosteroids, radiothe-
rapy or a combination of both. The success rate of corticoste-
roid therapy is 65%, but this is achieved at the cost of signifi-
cant morbidity. Almost one-third of the patients will experience
the well-known and frequent side effects of this kind of treat-
ment; and exacerbation following withdrawal is frequent(17,28).
Radiotherapy appears to be effective in some centers(29), but
without beneficial therapeutic effect in others(30-31). There are
other options for the treatment of GO, with similar response
rates, but seldomly indicated, as immunoglobulins, cyclospo-
rine A, octreotide, azathioprine, cyclophosphamide and pen-
toxyfylline(2,28,32). Another suggestion is the use of antagonists
of cytokines(26,33-36), since there is evidence that citokynes, i.e.,
IL-1, IL-2, IL-4, IL-5, IL-10, interferon-γ and TNF-α, produced by
orbital macrophages and fibroblasts or by infiltrating activated
lymphocytes, are potent stimulators of GAG synthesis and
other immunomodulatory proteins, like intercellular adhesion
molecules and heat shock protein-72)(33-36). However, their prac-
tical use in chronic disease states is limited by the need to
deliver these proteins parenterally. Additionally, studies are
required to establish the safety, effectiveness, and the favora-
ble cost-benefit ratio of these agents(33-36).
In this prospective and randomized trial, colchicine was
used for the first time in the treatment of the inflammatory
phase of GO and its effect compared with prednisone, the drug
considered to be the first choice in the treatment of this di-
sease. Patients were euthyroid throughout the period of ob-
servation, and an interval of 3 months between therapy and
assessment of therapeutic outcome was observed, in order to
make spontaneous improvement less likely.
The response to therapy in GO is difficult to assess; as a
result, several parameters have been evaluated. Among them,
it is reported that a higher T2 relaxation time indicates inflam-
mation rather than fibrosis and that the cause of the elevated
T2 relaxation time is due to the increased water content of the
retroorbital tissues(17). In this trial we used the combination of
the clinical activity score (CAS)(18-19) and the signal intensity
ratio on MRI (SIR)(20-21) and showed that the therapeutic out-
come in patients after 3 months of colchicine was equally
effective and better tolerated than prednisone, with 72% of
orbits responding to colchicine. Considering an improvement
of at least 2 points in CAS, 68% of orbits showed amelioration
of activity of the disease. Furthermore, of considerable impor-
tance is the fact that all patients receiving colchicine did not
present side effects; on the other hand, there were complaints
related to steroids in six prednisone-treated patients, besides
those two patients initially excluded from the trial. The evalua-
tion of signal intensity ratio on MRI after treatment also revea-
led a significant reduction in both groups; in G1 the therapeu-
tic outcome was effective, demonstrating that colchicine is a
valuable agent in the reduction of soft tissue inflammation.
The sites where colchicine might act include chemotaxis,
phagocytosis, adherence of polymorphonuclear cells, fibro-
blast proliferation and collagen synthesis rate, as well as inhi-
bition of cytokines (e.g. IL-1, IL-6, TNF-α, TGF-β)(8-9,37-38). Fur-
thermore, colchicine also downregulates the surface expression
of intercellular adhesion molecule-1(39). The inhibition of leuko-
cyte adhesion, fibroblast proliferation and cytokine release may
cause a reduction of GAG secretion and an inhibition of the
inflammatory cascade.
In this study, the smokers, as expected, had more severe
ophthalmopathy than the nonsmokers. Smoking can decrease
immunosuppression, allowing greater expression of the auto-
immune process(40-41). Our results, comparing smokers and
nonsmokers, independently of the used drug, indicate that
there was a tendency for nonsmokers to present lower values
Figure 2 - Comparison of the signal intensity ratio (SIR) of the two more
inflamed orbital muscles of patients with Graves’ ophthalmopathy
before and after treatment with colchicine (G1) or prednisone (G2); under
both treatments a significant reduction of SIR was observed (p=0.01 for
colchicine-treated group and p=0.01 for prednisone-treated group)
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of initial CAS (p=0.08). In addition, 10 of 15 smokers (66%)
were considered responders, compared with 18 of 19 (94%)
nonsmokers; although there was not a significant statistical
difference, the nonsmokers showed a higher percentage of
cure of inflammation. Since the value of p=0.06 is very close to
the critical rate, this can suggest a tendency of a higher proba-
bility of cure among nonsmokers, as it has been the experience
of others(2).
In conclusion, colchicine had a beneficial effect on the
inflammatory phase of Graves’ ophthalmopathy, providing
symptomatic relieve, reduction of clinical activity score and
signal intensity ratio; in addition, in this study it was equally
effective when compared to the classic treatment with corti-
costeroids, but safer and better tolerated and did not present
side effects when used in the proposed dose. Therefore, it is a
new option for patients with GO and can be used for a prolon-
ged time, avoiding recurrence of the disease.
RESUMO
Objetivo: Investigar se a colchicina é eficaz no tratamento da
oftalmopatia de Graves, nós comparamos o seu efeito com a
prednisona em 22 pacientes tratados na fase inflamatória da
doença. Métodos: Todos os pacientes, similares quanto à
idade, sexo e hábitos de tabagismo, estavam em eutiroidismo
por pelo menos três meses e foram randomizados em dois
grupos. O grupo 1 (G1) recebeu colchicina (1,5 mg/dia) e o
grupo 2 (G2) foi tratado com prednisona (0,75 mg/kg/dia). Os
pacientes foram acompanhados com avaliação oftalmológica
(escore de atividade clínica - CAS) e de imagem por meio da
ressonância magnética, usando a relação da intensidade de
sinal (SIR) dos músculos reto em comparação com a substân-
cia alba cerebral. Resultados: Diminuição no CAS de 68% foi
notada em ambos os grupos. A SIR também apresentou redu-
ção significante após o tratamento: A mediana inicial do G1 de
1,14 e 1,27 do G2 diminui após o tratamento para 1,07 no G1 e
0,69 no G2. A variação entre os grupos após o tratamento não
foi significante (p=0,22). Nenhum paciente tratado com colchi-
cina apresentou efeito colateral; ao passo que os efeitos cola-
terais no G2 foram ganho de peso, edema, queixas gástricas,
fraqueza, depressão e alteração na pressão arterial. Conclu-
são: A colchicina apresenta efeitos benéficos na fase inflama-
tória da oftalmopatia de Graves sem os efeitos colaterais da
prednisona.
Descritores: Oftalmopatia de Graves/quimioterapia; Colchici-
na/uso terapêutico; Prednisona/efeitos adversos; Tabagis-
mo; Estudos prospectivos
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